
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is a domain leader in transcranial magnetic stimulation, PBWAY has demonstrated their ability to optimize profitability through recurring revenue streams, this is expected to continue as their pipeline expands and reimbursement options grow; securing a whopping $78.5M in revenue in the past 12-month period, BrainsWay's total firm value is evaluated at ~$800M using a 5.6x sales multiple. There are limited risks to BrainsWay's growth and valuation as the company has a strong foundation in the market, a diverse pipeline, and multiple treatment options for various indications.
Bears say
BrainsWay is set to face challenges as it aims to expand its Deep TMS technology beyond its current indications and into new patient populations, as evidenced by its publication of a pilot study for the use of Deep TMS in patients with MDD and co-occurring early-stage Alzheimer's disease. While the results of this study showed promising results in both clinical outcomes and brain activity changes, it was conducted on a small sample size, and further trials would be necessary to support label expansion. Additionally, slower than projected uptake of Deep TMS systems, failure to expand reimbursement and market access, and potential long-term dilution risks could pose challenges for the company's growth and achievement of its $19 per share price target.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares